Hledání v detailu akcií
Top akcie
NázevNávštěvy
19 188
879
854
807
610
539
528
384
378
374
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN82,8-0,24
Msft-0,72
Nokia5,0645,0921,11
IBM0,02
DCX57,5657,57-0,31
PFE0,58
23.6.2018 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 22.6.2018 17:07:21
22nd Century Group (Stuttgart)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
1,83 2,23 0,04 40 260
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 24.6.2018
Popis společnosti
Obecné informace
Název společnosti22nd Century Group Inc
TickerXXII
Kmenové akcie:Ordinary Shares
RICXXII.K
ISINUS90137F1030
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 79
Akcie v oběhu k 3.5.2018 124 311 087
Počet akcionářů k 31.12.2017 98
MěnaUSD
Kontaktní informace
Ulice9530 Main St
MěstoCLARENCE
PSČ14031-1915
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 162 701 523
Fax17168773064

Business Summary: 22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.
Financial Summary: BRIEF: For the three months ended 31 March 2018, 22nd Century Group Inc revenues increased from $2.2M to $6.1M. Net income totaled $1.4M vs. loss of $2.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Unrealized gain on investment increase from $346K to $6.1M (income), Interest Income increase from $16K to $252K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Environmental Biotechnology
RBSS2004Investment Trusts
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSOffices of Other Holding Companies
SICCigarettes
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 24.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorHenry Sicignano482.3.201525.1.2011
Chief Financial Officer, TreasurerJohn Brodfuehrer581.4.20131.4.2013
Vice President, General Counsel, SecretaryThomas James5712.5.201412.5.2014
Vice President - Plant BiotechnologyPaul Rushton5330.10.201530.10.2015
Vice President - Research & DevelopmentJuan Tamburrino-31.12.201731.12.2017